What Is the Impact of Late-Onset Cytomegalovirus Disease After Valganciclovir Prophylaxis in Kidney Transplantation?

被引：9
|
作者：
Lamoth, Frederic [1 ,2 ,3 ]
Manuel, Oriol [1 ,2 ,3 ]
Venetz, Jean-Pierre [2 ,3 ]
Faouzi, Mohamed [2 ,4 ]
Meylan, Pascal [1 ,2 ,5 ]
Pascual, Manuel [2 ,3 ]
机构：
[1] CHU Vaudois, Infect Dis Serv, Dept Med, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne, CH-1015 Lausanne, Switzerland
[3] CHU Vaudois, Transplantat Ctr, CH-1011 Lausanne, Switzerland
[4] CHU Vaudois, Inst Social & Prevent Med, Ctr Clin Epidemiol, CH-1011 Lausanne, Switzerland
[5] CHU Vaudois, Inst Microbiol, CH-1011 Lausanne, Switzerland
来源：
TRANSPLANTATION | 2008年 / 86卷 / 09期
关键词：
D O I：
10.1097/TP.0b013e3181890788
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1323 / 1324
页数：2
相关论文
共 50 条
  • [1] No detectable indirect effects of late-onset Cytomegalovirus disease after valganciclovir (VGC) prophylaxis in kidney transplant recipients
    Lamoth, Frederic
    Manuel, Criol
    Meylan, Pascal R.
    Venetz, Jean-Pierre
    Faouzi, Mohammed
    Pascual, Manuel
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : S13 - S13
  • [2] No evidence of indirect effects of late-onset cytomegalovirus (CMV) disease after valganciclovir (VGC) prophylaxis in kidney transplant recipients
    Manuel, Oriol
    Lamoth, Frederic
    Meylan, Pascal R.
    Fellay, Jacques
    Venetz, Jean-Pierre
    Pascual, Manuel
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 527 - 527
  • [3] Extended Valganciclovir Prophylaxis Does Not Prevent Late-Onset Cytomegalovirus Disease in Kidney Transplant Recipients.
    Kalpoe, Jayant S.
    Sehgal, Vinita
    Bindal, Sapan
    Huprikar, Shirish
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 550 - 551
  • [4] Anemia as very late-onset cytomegalovirus disease after kidney transplantation
    Hernandez-Gallego, Roman
    Cerezo, Isis
    Roberto Robles, Nicolas
    Barroso, Sergio
    Romanciuc, Adrian
    Jose Cubero, Juan
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2018, 20 (01)
  • [5] Clinical Characteristics of Late-Onset Cytomegalovirus Infection After Kidney Transplantation
    Nuansri, Sirapob
    Kantachuvesiri, Surasak
    Watcharananan, Siriorn P.
    Thongprayoon, Charat
    Cheungpasitporn, Wisit
    Bruminhent, Jackrapong
    [J]. TRANSPLANTATION PROCEEDINGS, 2021, 53 (07) : 2267 - 2271
  • [6] Impact of Corticosteroid and Tacrolimus Minimization with Thymoglobulin Induction on Late-Onset Cytomegalovirus Disease in Kidney Transplantation
    Govani, M. V.
    Crone, C.
    White, R.
    Wee, A.
    Weiss, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 471 - 471
  • [7] Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease
    Singh, N
    Wannstedt, C
    Keyes, L
    Gayowski, T
    Wagener, MM
    Gacciarelli, TV
    [J]. TRANSPLANTATION, 2005, 79 (01) : 85 - 90
  • [8] Splenectomy for ABO-Incompatible Kidney Transplantation and Very Late-Onset Cytomegalovirus Disease
    Iwai, Tomoaki
    Uchida, Junji
    Kosoku, Akihiro
    Kabei, Kazuya
    Nishide, Shunji
    Naganuma, Toshihide
    Maeda, Keiko
    Yoshikawa, Yuki
    Kumada, Norihiko
    Takemoto, Yoshiaki
    Nakatani, Tatsuya
    [J]. UROLOGIA INTERNATIONALIS, 2020, 104 (7-8) : 651 - 656
  • [9] Late-onset Cytomegalovirus (cmv) Infection In Pediatric Kidney Transplantation Is Not A So Rare Disease
    Dehoux, Laurene
    Maisin, Anne
    Dossier, Claire
    Kwon, Theresa
    Macher, Mariealice
    Deschenes, Georges
    Baudouin, Veronique
    [J]. PEDIATRIC NEPHROLOGY, 2014, 29 (09) : 1764 - 1765
  • [10] Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation
    Ciancio, G
    Burke, GW
    Mattiazzi, A
    Leibovici, Z
    Dowdy, L
    Roth, D
    Kupin, W
    Rosen, A
    Jorge, D
    Cirocco, RE
    Miller, J
    [J]. CLINICAL TRANSPLANTATION, 2004, 18 (04) : 402 - 406
12345